Skip to main content

Catalyst Calendar

Scope

Wed, Oct 7, 2026

1 updates

Thu, Oct 1, 2026

1 updates
OCS
2:00 AM

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG

oculis.com

Wed, Sep 30, 2026

1 updates
OCS
5:32 PM

Oculis Announces Resignation of Lionel Carnot from Board of Directors

Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in

oculis.com

Thu, Sep 17, 2026

1 updates

Mon, Aug 24, 2026

1 updates
OCS
4:00 AM

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough Therapy and EMA PRIME designations, and recent positive feedback from the FDA Neurology Division.

Trial Start • Phase 3Trial initiation Mon, Aug 24, 2026oculis.com